Related Experiment Video
Updated: Jun 26, 2026

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
Published on: January 31, 2020
Risankizumab: Daily Practice Experience of High Need Patients
Alexandra M G Brunasso1, Martina Burlando2,3, Fabrizio Amoruso4
1Department of Internal Medicine, Villa Scassi Hospital ASL3, 16100 Genoa, Italy.
Risankizumab effectively treats moderate to severe plaque psoriasis, including difficult-to-treat locations. This real-world study shows rapid symptom relief and disease remission with risankizumab, a biologic targeting interleukin-23.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Psoriasis is a chronic inflammatory condition impacting millions globally.
- Special localizations like nails and face significantly reduce quality of life.
- Interleukin-23 (IL-23) is a key cytokine in psoriasis pathogenesis.
More Related Videos
06:19Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
Published on: May 31, 2024
04:50Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Related Concept Videos
Patient-centered Care
Methods of Documentation VI: Case Management Model
For example, a patient with a chronic illness...
Documentation in Long-Term and Home Healthcare Setting
Long-Term Care Facilities
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Kidney Transplant III: Nursing Management
Chronic Kidney Disease III: Interprofessional Care